Citigroup Maintains Buy Rating on Mirum Pharmaceuticals Shares
Citigroup kept its Buy rating on Mirum Pharmaceuticals, according to the Benzinga analyst-ratings page for the MIRM ticker.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Citigroup has maintained its Buy rating on Mirum Pharmaceuticals, according to information published in Benzinga’s analyst-ratings section.
The update concerns the MIRM ticker; the report does not specify any change to the recommendation.
why it matters
For markets, the update indicates that Citigroup has not changed its view on Mirum Pharmaceuticals; no new price target or forecast details were provided.
instruments
sources
- Mirum Pharmaceuticals Is Maintained at Buy by Citigroup — Newsmetry API, 12 October 2026 at 21:13 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗